IQVIA Holdings (IQV) is back in focus after its latest earnings report, where solid fourth quarter revenue and an earnings beat met softer profit guidance for 2026, shifting the market’s attention toward future profitability.

That cautious 2026 profit outlook has fed into IQVIA Holdings' share price performance, with a 7 day share price return of 18.54% and a 30 day share price return of 22.66%, while the 1 year total shareholder return of 9.92% and 3 year total shareholder return of 15.86% point to fading momentum over a longer horizon as investors weigh growth investments against higher interest costs and margin pressure.

If earnings volatility has you reassessing your options in healthcare data and clinical trials, it could be a good time to scan for other life sciences names using our screener of 26 healthcare AI stocks.

With IQVIA trading around US$187.49, a reported intrinsic discount of about 40% and a sizeable gap to analyst targets, the real question is whether this is mispricing or whether the market is already factoring in its future growth potential.

Most Popular Narrative: 25% Undervalued

The most widely followed narrative puts IQVIA Holdings' fair value at about $250 per share, comfortably above the last close of $187.49 and framing a sizeable valuation gap that analysts tie to long term earnings power rather than short term swings.

Record R&D Solutions backlog and strong sequential increases in qualified pipeline and RFP flow indicate sustained demand for outsourced clinical research, particularly in oncology, cell & gene therapies, and novel therapeutic areas, which should translate into resilient, long-term contracted revenues and improved earnings visibility.

Curious how that backlog, projected revenue growth, and margin assumptions line up to support a higher fair value and future earnings profile, and what earnings multiple analysts think ties it all together over the next few years? The full narrative lays out the chain of assumptions step by step without leaving the numbers to guesswork.

Result: Fair Value of $250 (UNDERVALUED)

However, there is still a risk that ongoing pricing pressure in CRO contracts and IQVIA's higher debt load could weigh on margins and limit flexibility if conditions tighten.

Build Your Own IQVIA Holdings Narrative

If you look at the numbers and reach a different conclusion, or just prefer to work from your own research, you can build a custom thesis in a few minutes using Do it your way.

A great starting point for your IQVIA Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If IQVIA has sharpened your focus on quality, do not stop here. Use the Simply Wall St screener to spot other opportunities before the crowd moves.

• Target long term value by reviewing companies our screener flags as 52 high quality undervalued stocks based on strong fundamentals and pricing that may not fully reflect their potential.
• Prioritise resilience by filtering for businesses in our 82 resilient stocks with low risk scores that pair lower risk scores with more measured financial profiles.
• Hunt for lesser known opportunities using our screener containing 24 high quality undiscovered gems, where solid fundamentals meet relatively limited investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.